中国药业2025，Vol.34Issue(10)：119-123,5.DOI:10.3969/j.issn.1006-4931.2025.10.026
达格列净联合二甲双胍治疗2型糖尿病并心血管疾病药物经济学评价
Pharmacoeconomic Evaluation of Dapagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus with Cardiovascular Disease
摘要
Abstract
Objective To provide a reference for the selection of clinical treatment options for type 2 diabetes mellitus(T2DM)with cardiovascular disease.Methods Using real-world data,129 patients with T2DM with cardiovascular disease were included.and divided into the observation group(received dapagliflozin combined with metformin)and the control group(received metformin),according to different medication regimens,and matched by propensity score matching method.The fasting blood glucose(FBG),2-hour postprandial glucose(2 hPG)levels before and after treatment,clinical efficacy,andtreatment costs of disease were compared between the two groups of patients.The cost-effectiveness ratio(C/E)and the incremental cost-effectiveness ratio(ICER)were calculated,and the sensitivity analysis was performed on the results.Results The levels of FBG and 2 hPG in the two groups were significantly decreased after treatment(P<0.05);and the level of 2 hPG in the observation group was significantly lower than that in the control group(P<0.05).The total effective rate in the observation group was 77.36%,which was significantly higher than 58.49%in the control group(P<0.05).The median total cost in the observation group was CNY 745 higher than that in the control group,but its C/E was lower(118.79 vs.144.38).The ICER in the observation group was 39.48.The sensitivity analysis showed that the results was robust.Conclusion Compared with metformin monotherapy,dapagliflozin combined with metformin in the treatment of patients with T2DM with cardiovascular disease can significantly improve 2 hPG,and its advantages of pharmacoeconomic are more obvious.关键词
2型糖尿病/心血管疾病/达格列净/二甲双胍/药物经济学Key words
type 2 diabetes mellitus/cardiovascular disease/dapagliflozin/metformin/pharmacoeconomics分类
药学引用本文复制引用
黄凯钰,张宇杭,应婷,夏茹楠,赵琛健,徐杏涓,王亚东,解雪峰..达格列净联合二甲双胍治疗2型糖尿病并心血管疾病药物经济学评价[J].中国药业,2025,34(10):119-123,5.基金项目
安徽省教育厅安徽高校协同创新项目[GXXT-2021-068]. （）
